Low fruit and vegetable consumption is linked with an increased risk of all cause mortality and death from several conditions including vascular disease and cancer. Nutritional, Metabolic, Endocrine
Conditions
Interventions
Prospective volunteers are asked to fill out a questionnaire about their health, level of exercise and medication. They are then grouped by gender, and brigade based on BMI and age, and then randomize
weeks 0-20). Biological sampling (blood, urine and faeces) takes place on a total of 6 days. Base-line sampling is at week 0
intervention is for a total of 12 weeks (week 2-14) with sampling at the start of intervention (week 2) and at the end of each intervention month (week 6, 10 & 14)
washout sampling is at week 20 . Weighed intake diaries are also collected during lead-in week , 2nd and 10th week of intervention and last week of washout.
1. Weighing and blood press
Sponsors
University of Aberdeen
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Habitually consume less than 2 portions of fruits and vegetables per day 2. Healthy 3. Aged between 38 and 60 years 4. Body mass index between 18 and 39 5. Non-smoker 6. Resident of North East Scotland
Exclusion criteria
Exclusion criteria: 1. Regularly consume > 3 portions of fruit & vegetables per day 2. Smoker 3. Have a chronic medical condition e.g. inflammatory bowel disease, gall bladder disorder, diabetes, heart disease, cancer 4. Have a known allergy to any fruit or vegetables 5. Have given a large blood donation in the last three months 6. Taking any of the following medication: 6.1. Drugs to lower high cholesterol levels (HMG CoA reductase inhibitors) 6.2. Drugs to lower high blood pressure (calcium channel antagonists) 6.3. Non-sedating antihistamine 6.4. Drugs used in immuno-suppression therapy following transplantation 6.5. Drugs used in AIDS therapy 6.6. Drugs to lower inflammation (non-steroidal anti-inflammatories) 6.7. Aspirin (on a regular basis)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Plasma vitamin C concentration measured by high performance liquid chromatography (HPLC). ((baseline; weeks 0, 2), intervention (weeks 6, 10 and 14) and washout (week 20)). 2. Plasma vitamin E (alpha and gamma-tocopherol) concentration measured by HPLC. ((baseline; weeks 0, 2), intervention (weeks 6, 10 and 14) and washout (week 20)). 3. Plasma carotenoids (alpha-carotene, beta-carotene, beta-cryptoxanthin, lutein/zeaxanthin concentrations measured by HPLC. ((baseline; weeks 0, 2), intervention (weeks 6, 10 and 14) and washout (week 20)). Whole blood folate and plasma B12 measured by radioassay ((baseline; weeks 0, 2), intervention (weeks 6, 10 and 14) and washout (week 20)). 4. Plasma concentrations of vitamins B2 and B6 measured by HPLC. [(baseline; weeks 0, 2), intervention ((baseline; weeks 0, 2), intervention (weeks 6, 10 and 14) and washout (week 20)). 5. Total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides (TG) and glucose measured using a Konelab 20 Clinical Chemistry Analyser (Thermo Scientific, Passau, Germany). ((baseline; weeks 0, 2), intervention (weeks 6, 10 and 14) and washout (week 20)). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Genotoxicity: Single cell gelectrophoresis (SCGE) is used to determine lymphocyte genostability and the influence of recovered faecal waters on established culltured colon epithelial cell line (e.g. HT-29, NCM460, RKO, RKO-E6, Caco-2) genostability in vitro.((baseline; weeks 0, 2), intervention (weeks 6, 10 and 14) and washout (week 20)). 2. Phenolic and related metabolites will be determined in blood and faecal waters by the colorimetric Folin-Ciocalteu micro-method and by LC-MS. ((baseline; weeks 0, 2), intervention (weeks 6, 10 and 14) and washout (week 20)).. These are also determined in urine (week 0 and 14, only). 3. Plasma homocysteine determined by high-performance liquid chromatography (HPLC). | — |
Countries
United Kingdom
Contacts
Public ContactSylvia Stephen
Outcome results
None listed